Variable bioreactors have been developed for the evaluation of anti-cancer drug efficacy. The Kinetic and Static Alternating Cell Culture System (KSACCS) combines the advantages of kinetic bioreactors and static cultures to improve cell growth by providing adequate metabolic support while minimizing shear-stress. In the current studies, the KSACCS in the ZYX Bioreactor could significantly increase the sensitivity of lung cancer cells (PLS008) and leukemia cells (HL60) to anticancer drugs Cisplatin and 5-FU by accelerating the apoptosis of cancer cells. It was also shown that excessive agitation of the cells could lead to severe cell damage, which resulted in a diminished sensitivity of anticancer drug evaluation, and co-culture systems tend to reduce the sensitivity of anticancer drug evaluation although it might better mimic in vivo conditions.
Introduction
Rapid and accurate evaluation of anti-cancer drug efficacy is particularly important for anticancer drug screening for cancer patients who will undergo chemotherapy and for the research and development of anticancer medicine. Many efforts have been devoted to the development of in vitro culture systems that more effectively mimic the in vivo environment [1] [2] [3] [4] [5] . Currently, several in vitro culture systems or in vivo animal models are the primary tools used to test cancer cell responses to drugs [3] [4] [5] . However, drug sensitivity data ob-human tissue or cells as supporting materials may produce responses more predictive of humans than animal models.
A proper representation of the tumor microenvironment is extremely critical for testing the effectiveness of anti-cancer drugs. Since cancer cells in the body exist physically in two main forms, kinetic as in hematopoietic and lymphoid malignancies and static as in solid tumors, an ideal bioreactor system should be able to mimic these two forms in its potential application in anti-cancer agent screening and evaluation. Leukemia cells may spend a majority of their time in peripheral circulation but also reside in the bone marrow. In contrast, most solid tumor cells, such as those in lung and liver cancers, mostly grow in a unique area of the body, save late stage metastatic spread. To mimic these two physical forms in which cancer cells exist in the body, an ideal bioreactor must allow cells to grow well in both static and kinetic states, and these two states should ideally be controlled and regulated in a dynamic fashion by automated control systems. Unfortunately, current commercially-available 3D bioreactors can only maintain cells in either a kinetic state (K bioreactor) [1] [2] [5] [6] [7] or a static state (S bioreactor) [1] [2] [3] [4]. When cells are cultured in a K bioreactor [5] [6] [7] , they are kept in motion by agitation or similar mechanism, accumulating at fixed points within the bioreactor when agitation ceases. Cell accumulation adversely affects the growth of cells in culture as cells in the center of the accumulation experience hypoxic conditions and lower concentrations of anti-cancer drugs in the medium. On the other hand, cells in S bioreactors are usually supported by gel-like materials which prevent them from moving as they would in peripheral circulation. Therefore, neither the K bioreactor nor S bioreactor meets the requirements for both of the above two physical states.
The ZYX bioreactor system used in this study enables programmed control of many culture parameters. This allows the bioreactor to gently maintain cells in suspension for kinetic cultures and provide an even distribution for static cultures, allowing cells to grow well in both physical states [15] . The advantages of ZYX bioreactor have been well-demonstrated in the culture of stem cells and immunocytes [15] [16] . The current study further confirms the advantages of the ZYX bioreactor by mimicking both kinetic and static states of cancer cell survival in the body to improve the objectivity and accuracy of anti-cancer agent screening and evaluation in vitro. 
Establishing a Co-Culture Model to Mimic the Tumor Growth Microenvironment
Fibroblasts [17] [26] with 6 mm-diameter cell carriers were co-cultured with HL60, in which the media contained human recombinant fibroblast growth factor 9 (FGF9, 10 ng/ml) (R & D Systems, Minneapolis, MI). Two weeks later, suspension cells were harvested and viable cells were assessed as described above. Cultures were grouped based on the application of fibroblasts and the addition of Cisplatin and 5FU. Each group contained 4 cultures.
Analysis of the Efficiency, Sensitivity, and Reproducibility of Anti-Cancer Drug Evaluation
Efficiency was evaluated by measuring the rate of response to the anti-cancer drug (greatest response over the shortest culture incubation time in which anti-cancer drug efficacy could be determined). Sensitivity was evaluated by comparing different culture methods at the same concentration of the drug that showed efficacy. This could also be used to compare the relative effectiveness of various drugs. Reproducibility was evaluated by comparing the coefficients of variation between the cultures with the selected ZYX Bioreactor program and traditional static cultures.
Statistics Analysis
ANOVA and Student t-test were used for comparison of means, including those for cell number and their percentages. Reproducibility was evaluated with coefficient of variations (CV = standard deviation/mean × %). P < 0.05 was considered as significant. 
Results

Increased Proliferation of Cancer Cells in the ZYX Bioreactor
Human breast (MCF-7), prostate (PC-3), ovary (PA-1), cervix (HeLa S3), Leukemia HL-60 and lung cancer cells (PLS008) were cultured at proper seeding densities. On culture day 6, all adherent cells were trypsinized using standard procedure prior to analysis whereas suspension cells were analyzed directly. ZYX Bioreactors with program K2 were compared to six well plates as the static culture controls. Figure 1 shows that all cancer cells grew significantly faster in the ZYX bioreactor than in 2D static culture (P < 0.01, n = 4/each condition).
Increased Effects of Anti-Cancer Drugs to Cancer Cells in the ZYX Bioreactor with Program K2
PLS008 , prostate (PC-3), ovary (PA-1), cervix (HeLa S3), Leukemia HL-60 and lung cancer cells (PLS008) were cultured at proper seeding densities, and on culture day 6, all adherent cells were trypsinized using standard procedures prior to analysis whereas suspension cells were analyzed directly. Cultures from ZYX Bioreactors with the program K2 were compared to used as the static culture controls grown in six well plates. Figure 1 shows that all cancer cells grew significantly faster in the ZYX bioreactor than in 2D static culture (P < 0.01, n = 4). less) but showed the same trends as Annexin V (data not shown).
Dose-Effect Relationship of Anticancer Drugs in ZYX Bioreactor Cultures
Lung cancer cells PLS008 were used for the evaluation of dose-effect relationship in responses to cisplatin and 5FU. As the dose (concentration) of anticancer drug increased, the lung cancer cell number significantly reduced, and the cell number change was negatively correlated (P < 0.01, R = −0.82) to the anticancer dose (concentration). When the data was analyzed in semi-Log, the curves were more linearized. Increasing drug dose appeared to cause a logarithmic drop in cell numbers (Figure 3(b) ). The significant difference between Cisplatin and 5FU can be seen at 1 µmol/L in the culture with ZYX bioreactor program K2 but such a difference can be seen on day 6 in the static culture (program K0). Figure 3 . Dose-effect relationship of Cisplatin and 5FU in lung cancer cell PLS008. PLS008 cells were cultured with 0, 1, 2.5, 5 and 10 µmol/L Cisplatin or 5FU for 8 days, the dose-effect curves were plotted directly (a) or in semi-Log (b). Compared to (a), the dose-effect curves in (b) are more linearized and show PLS008 was more sensitive to the increasing concentrations of both Cisplatin and 5-FU (P < 0.05 -0.01). Five different ZYX bioreactor programs were used for the culture of PLS008 and HL-60 cells with Cisplatin, 5FU or a no-drug control. Program K0 is for a static culture, K1 is for 1 unit (5 minutes, once per day) of kinetic culture per day and increases the length of the kinetic culture unit with increasing cell density, K2 is for 2-units (5 minutes, twice per day) of kinetic culture per day and increases the length of the kinetic culture unit with increasing cell density, K3 is for 3-unit (5 minutes, 3 times per day) kinetic culture per day and increases the length of the kinetic culture unit with increasing cell density, and Kf is for a completely kinetic culture. For the culture without anti-cancer drugs, cell densities increased as the kinetic portion of the culture did, starting with K0 and reaching a peak level with program K2. From that point densities declined rapidly ((a)-(c)). The differences between adjacent programs are significant (P < 0.01). Partial kinetic cultures (K1, K2, and K3) also exhibited significant differences between Cisplatin and 5FU (P < 0.05 -0.01), but purely static (K0) and purely kinetic cultures (Kf) did not ((b) and (d)). 
Effect of Different ZYX Bioreactor Programs on the Sensitivity of Anticancer Drugs to Cancer Cells
Decreased Sensitivity to Anticancer Drugs in HL60 Cells Co-Cultured with Fibroblasts
Co-culturing cancer cells with supporting cells provides them with a test environment more similar to in-vivo conditions. Fibroblast support cell cultures were grown to 80% confluence. At that point, all media was removed and HL60 cells were added in media containing either 5FU or Cisplatin. Figure 5 shows that co-cultured HL60 cells were significantly less sensitive to both 5FU and Cisplatin than cultures without supporting cells from day 4 to day 8. Moreover, there was a significant differences between cell numbers in Cisplatin and 5FU
cultures without supporting cells on days 4, 6 and 8, but this difference can only seen on the days 6 and 8 in the co-cultured cells. Figure 5 . Effects of supporting cells on the sensitivity of cancer cells to anticancer drugs. HL60 cells cultured in media containing anti-cancer drugs Cisplatin and 5FU exhibited a decline in cell density over the course of the culture. Cultures with both drugs exhibited a significantly smaller decline from day 4 to day 8 when the cells were seeded with 80% confluent fibroblasts (P < 0.05 -0.01). A significant difference could be observed between Cisplatin and 5FU in the co-cultures at day 6 and day 8, and in the culture without supporting fibroblasts at day 4 through day 8. 
Evaluation of the Reproducibility of ZYX Bioreactor Programmed Cell Culture in Testing the Sensitivity of Anticancer Drugs
The coefficients of variation (CV) from 56 pairs of tests (each test has 4 observations, total 448 observations) with the static culture and ZYX Bioreactor programmed cultures were compared and the difference of CVs between these two culture methods was not significant (P > 0.5), indicating that the reproducibility of ZYX Bioreactor programmed cell culture is similar to static culture ( Figure 6 ).
Discussion
Most anti-cancer drugs works more efficiently on faster proliferating cancer cells and cancer cells can grow faster under more suitable culture conditions. Thus, improving the cell growth conditions could make the evaluation of drug efficacy more efficient.
In this study, we showed that culture conditions with alternating kinetic and The window for observing the dose-effect relationship between anti-cancer drugs and in vitro cultured cancer cells is relatively narrow since the toxicity of the drug often leads the cells death in the early stages of the culture. For this reason, most of the tests in the current study were limited to 8 days. As shown in Figure 3 , even at 1 µmol/L of Cisplatin or 5FU caused a sharp drop in the number of live lung cancer cells. The two drugs had significantly different efficacy which was clearly exhibited at all tested doses in cultures grown in the ZYX bioreactor with program K2 but not in static cultures (Figure 3(b) ).
ZYX Bioreactor is a programmable automatic cell culture system with many internal programs. These programs can determine various culture parameters including the kinetic/static status. To test if increasing the kinetic portion of the culture could further elevate the efficiency of the evaluation of anti-cancer drugs, 5 different programs were selected. These ranged from completely static (K0) to completely kinetic (Kf) and were applied in the experiment as shown in Figure  4 . The program K2 was found to be optimal in non-treatment control cultures as described above. This program was also best at differentiating between the effectiveness of Cisplatin and 5FU on cancer cell cultures (Figure 4 (b) and Figure  4 (d)), suggesting that the ZYX bioreactor can be used to optimize culture conditions and improve the sensitivity of such drug evaluations.
Flow cytometric analysis revealed that apoptotic Annexin V and PI-positive cells greatly increased in cancer cell cultures with program K3, which has a greater kinetic portion, and Kf, which is a purely kinetic program. This effect was evident in both untreated cultures and anti-cancer drug treated cultures. This is consistent with earlier findings which reported that ceaseless kinetic cultures resulted in damage to cell membranes and organelles and stimulated the nonspecific differentiation of stem cells due to the continuous shear-stress on the cells [7] [15]. Therefore, it is possible that the decreased sensitivity of anti-cancer drug evaluation and decline in untreated cell proliferation in cultures with a greater kinetic portion resulted from cell damage caused by excessive shear-stress.
Co-cultures with human tissues or human cells provide the cells with a more in-vivo-like growth environment, and may more reliably reflect bona fide effects of anti-cancer drug on cancer cells [12] [17] [20] . HL-60 is a leukemia cell line, which was originally supported by fibroblasts and mesenchymal cells in bone marrow. These supporting cells are biologically similar. When HL-60 cells were co-cultured with fibroblasts, the toxicity of anti-cancer drugs to the cancer cells was reduced and the sensitivity of the test was decreased, although co-cultured cells grown using the ZYX bioreactor program K2 might still perform better than static mono-cultures and could differentiate between Cisplatin and 5FU in 6 days compared to 8 days for static cultures (Figure 2 and Figure 5 ). Larger dose of drug or extended cultures may improve the effectiveness of anti-cancer drug test in co-cultures.
Coefficient of variation is often used to assess repeatability and reproducibility when replicate measurements by each method are available [33] [34]. Figure 6 . Comparison of reproducibility between static culture (K0) and the culture with peak ZYX Bioreactor program (K2). The coefficients of variation (CV) from 56 pairs of tests (each test has 4 observations) with the culture program K0 and K2 were compared and the difference between these two culture methods was not significant (P > 0.5).
Although the sensitivity of anticancer drug evaluation in cultures with the kinetic and static alternating program K2 in the ZYX Bioreactor is significantly greater than that of static cultures, these two methods exhibit similar mean coefficients of variation, suggestive of reliable reproducibility of tests comparing these culture systems.
Conclusion
Kinetic and static alternating cell culture could significantly increase the sensitivity of cancer cells to anticancer drugs, in which the accelerated apoptosis of cancer cells were involved. The excessive agitation of the cells could lead to severe cell damage, which resulted in a diminished sensitivity of anticancer drug evaluation. The co-culture systems might better mimic in vivo conditions but tend to reduce the sensitivity of anticancer drug evaluation. 
